New Treatment for Paediatric Crohn's Disease Now Available in the UK

     New Treatment for Paediatric Crohn's Disease Now Available in the UK

  PR Newswire

  MAIDENHEAD, England, January 16, 2013

MAIDENHEAD, England, January 16, 2013 /PRNewswire/ --

HUMIRA ® (adalimumab) is the first biologic treatment in more than five years
to be approved in the European Union for the treatment of severe active
paediatric Crohn ' s disease offering at-home administration  after suitable
training ^[ ^1] ^, ^[ ^2]

AbbVie announced today that HUMIRA® (adalimumab) is now available for the
treatment of paediatric patients aged six to 17 years with severe active
Crohn's disease (CD) who have had an inadequate response to conventional
therapy including primary nutrition therapy, a corticosteroid, and an
immunomodulator, or who are intolerant to or have contraindications to such
therapies. ^[1]

"Paediatric Crohn's disease is a chronic bowel disease that may have a
significant impact on a child or young person and his or her family's quality
of life," said Dr Richard Russell, Consultant Paediatric Gastroenterologist,
Royal Hospital for Sick Children, Glasgow. "The number of children and young
people diagnosed with Crohn's disease continues to rise in the UK but the
number of treatment options available remains limited. For patients who do not
respond to standard therapies, this new treatment option addresses a
significant unmet need by offering the flexibility of out of hospital
injectable administration, usually by patients or their parents." 

Paediatric Crohn's disease is a chronic condition of the gastrointestinal (GI)
tract. In the UK there are currently around 90,000 people living with Crohn's
disease, which can affect people of all ages, including children. ^[3]

As a type of inflammatory bowel disease, it most commonly involves the end of
the small intestine and the beginning of the large intestine. ^[3] In addition
to symptoms such as abdominal pain, weight loss and diarrhoea, paediatric
Crohn's disease can affect children in several ways unique to this age group,
including delayed growth and/or puberty. ^[4]

Richard Driscoll, Chief Executive of Crohn's and Colitis UK a charity which
provides information, support and research for people of all ages affected by
inflammatory bowel disease, said "Paediatric Crohn's disease is known to be
increasing in frequency among children and young adults of all ages. We
welcome this new treatment that is being made available in the UK as the
symptoms can be very severe and have a significant debilitating effect on the
child and their family."

"Whilst the psychological effects cannot be measured, symptoms, treatment and
side effects may mean that childhood and adolescence can be severely disrupted
making it difficult for some children to cope emotionally. Physical growth and
pubertal development can be delayed, creating an additional problem,
particularly in relation to school, college and social life" said Rod
Mitchell, Chairman of the Crohn's in Childhood Research Association (CICRA).

Notes to editors

About HUMIRA ^[1]

HUMIRA® (adalimumab) is a prescription medicine licenced for the treatment of
moderate to severe active rheumatoid arthritis, active polyarticular juvenile
idiopathic arthritis, active and progressive psoriatic arthritis, severe
active ankylosing spondylitis (AS), severe axial spondyloarthritis without
radiographic evidence of AS, moderately to severely active Crohn's disease and
ulcerative colitis in adults, severe active Crohn's disease in paediatric
patients, and moderate to severe chronic plaque psoriasis. Please refer to the
Humira Summary of Product Characteristics (SmPC) for full product information
which can be found at .

Adverse events should be reported. Reporting forms and information can be
found at . Adverse events should also be
reported to AbbVie Ltd on +44-(0)1628-774933.

About AbbVie

AbbVie (NYSE:ABBV) is a global, research-based biopharmaceutical company
formed in 2013 following separation from Abbott. AbbVie combines the focus and
passion of a leading-edge biotech with the expertise and structure of a
long-established pharmaceutical leader. The company's mission is to use its
expertise, dedicated people and unique approach to innovation to develop and
market advanced therapies that address some of the world's most complex and
serious diseases. AbbVie aims to help patients live healthier lives and
collaborate on sustainable healthcare solutions. In 2013, AbbVie will employ
approximately 23,000 people worldwide and markets medicines in more than 170
countries. For further information on the company and its people, portfolio
and commitments, please visit

1.  Humira Summary of Product Characteristics accessed via

2.  European Medicines Agency. Scientific discussion. 2007. Available from:
Last accessed December 2012

3.  NHS CHOICES. Crohn's disease. Available from: Last
accessed December 2012

4.  Mackner, L (2003). "Review: Psychosocial Issues in Pediatric
Inflammatory Bowel Disease" J. Pediatr Psychol. 29 (4): 243-257

Contact: Media enquiries, UK Communications, +44-(0)1628-644582
Press spacebar to pause and continue. Press esc to stop.